Voluntary Scheme for Branded Medicines Pricing and Access

Department for Science, Innovation and Technology written question – answered at on 17 March 2023.

Alert me about debates like this

Photo of Chris Green Chris Green Conservative, Bolton West

To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made for the implications for her policies of the recent analysis published by WPI Economics: False Economy Report on the impact of rebate rates under the Voluntary and Statutory Schemes for Branded Medicines Pricing and Access on the level of future R&D investment.

Photo of George Freeman George Freeman Minister of State (Department for Science, Innovation and Technology)

The Department carefully considers all evidence in the public domain on matters relating to the growth and competitiveness of the UK Life Science sector, including the recent report by WPI Strategy. This happens in combination with broad engagement with individual companies, the NHS and with charities and patient representatives, and will continue in future as part of the delivery of the Government’s Life Science Vision.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.